Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Acquisitions (2017)

Soleno Therapeutics (SLNO) has disclosed Acquisitions for 1 consecutive years, with -$408.0 as the latest value for Q4 2017.

  • On a quarterly basis, Acquisitions changed N/A to -$408.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $349592.0, a N/A change, with the full-year FY2017 number at $572592.0, changed N/A from a year prior.
  • Acquisitions was -$408.0 for Q4 2017 at Soleno Therapeutics, down from $350000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $350000.0 in Q3 2017 to a low of -$408.0 in Q4 2017.